Literature DB >> 23506565

What predicts adverse outcomes in untreated primary hyperparathyroidism? The Parathyroid Epidemiology and Audit Research Study (PEARS).

Ning Yu1, Graham P Leese, Peter T Donnan.   

Abstract

OBJECTIVE: This study aims to identify the best biochemical risk factors alongside other factors for predicting adverse outcomes seen in untreated primary hyperparathyroidism (PHPT).
DESIGN: Population-based cohort study, 1997-2006.
SETTING: Tayside, Scotland, UK. PATIENTS: Patients with untreated diagnosed PHPT. OUTCOME MEASURES AND METHODS: Outcomes considered were all-cause mortality, fatal and nonfatal cardiovascular disease (CVD). Models were derived using survival analysis. Potential biochemical predictors tested were baseline serum calcium, parathyroid hormone (PTH), creatinine and alkaline phosphatase (ALP), and other covariates considered were gender, age at diagnosis, deprivation, previous comorbidities and bisphosphonates usage.
RESULTS: From 1997 to 2006, 2097 patients (mean age, 68·4 years; 69·9% women) with untreated PHPT were identified with a total follow-up of 7338 person years, in the population of Tayside, Scotland. The median baseline calcium was 2·61 mm, and PTH was 7·2 pm. PTH was the only statistically significant risk factor in all outcomes observed adjusting for other covariates. Serum creatinine and ALP predicted mortality outcomes in the short term (≤3 years), but not long term. Calcium was associated with increased risk of all-cause mortality in the short term but had no significant impact on other outcomes.
CONCLUSION: Baseline PTH, rather than calcium, best predicts long-term outcomes in untreated PHPT.
© 2013 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23506565     DOI: 10.1111/cen.12206

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  10 in total

Review 1.  [Localization of parathyroid adenomas with C11-methionine PET-CT].

Authors:  T Weber; M Luster
Journal:  Chirurg       Date:  2014-07       Impact factor: 0.955

2.  PTH/PTHrP Receptor Signaling Restricts Arterial Fibrosis in Diabetic LDLR-/- Mice by Inhibiting Myocardin-Related Transcription Factor Relays.

Authors:  Abraham Behrmann; Dalian Zhong; Li Li; Su-Li Cheng; Megan Mead; Bindu Ramachandran; Parastoo Sabaeifard; Mohammad Goodarzi; Andrew Lemoff; Henry M Kronenberg; Dwight A Towler
Journal:  Circ Res       Date:  2020-03-11       Impact factor: 17.367

3.  Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease.

Authors:  S Geng; Z Kuang; P L Peissig; D Page; L Maursetter; K E Hansen
Journal:  Osteoporos Int       Date:  2019-05-31       Impact factor: 4.507

4.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

Review 5.  Primary hyperparathyroidism and hypertension.

Authors:  Sarah B Fisher; Nancy D Perrier
Journal:  Gland Surg       Date:  2020-02

6.  Primary hyperparathyroidism: findings from the retrospective evaluation of cases over a 6-year period from a regional UK centre.

Authors:  Joseph M Pappachan; Mohamed Nabil Elnaggar; Ravinder Sodi; Kahtan Jbeili; Paul R Smith; Ian M Lahart
Journal:  Endocrine       Date:  2018-07-17       Impact factor: 3.633

Review 7.  Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus.

Authors:  A A Khan; D A Hanley; R Rizzoli; J Bollerslev; J E M Young; L Rejnmark; R Thakker; P D'Amour; T Paul; S Van Uum; M Zakaria Shrayyef; D Goltzman; S Kaiser; N E Cusano; R Bouillon; L Mosekilde; A W Kung; S D Rao; S K Bhadada; B L Clarke; J Liu; Q Duh; E Michael Lewiecki; F Bandeira; R Eastell; C Marcocci; S J Silverberg; R Udelsman; K Shawn Davison; J T Potts; M L Brandi; J P Bilezikian
Journal:  Osteoporos Int       Date:  2016-09-09       Impact factor: 4.507

8.  Presentation, diagnostic assessment and surgical outcomes in primary hyperparathyroidism: a single centre's experience.

Authors:  Laura Reid; Bala Muthukrishnan; Dilip Patel; Mike Crane; Murat Akyol; Andrew Thomson; Jonathan R Seckl; Fraser Wilson Gibb
Journal:  Endocr Connect       Date:  2018-08-23       Impact factor: 3.335

9.  Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism.

Authors:  Samuel Frey; Raphaël Bourgade; Cédric Le May; Mikaël Croyal; Edith Bigot-Corbel; Nelly Renaud-Moreau; Matthieu Wargny; Cécile Caillard; Eric Mirallié; Bertrand Cariou; Claire Blanchard
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

Review 10.  Physical Activity-Dependent Regulation of Parathyroid Hormone and Calcium-Phosphorous Metabolism.

Authors:  Giovanni Lombardi; Ewa Ziemann; Giuseppe Banfi; Sabrina Corbetta
Journal:  Int J Mol Sci       Date:  2020-07-29       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.